Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IONIS PHARMACEUTICALS INC reported full year 2022 results: revenue >$575 million, net income <$350 million. Guidance raised.
- Period
- full year 2022
- Revenue
- >$575 million
- Net income
- <$350 million
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Item 2.02 Results of Operations and Financial Condition. In connection with the Company’s entry into the Agreement, the Company increased its full year 2022 guidance for operating expenses and net loss, on a non-GAAP basis, to incorporate the upfront payment to Metagenomi, all as reflected in the table below. Full Year 2022 Guidance Revised Guidance Previous As of Q3 2022 Revenue >$575 million >$575 million Operating expenses on a non-GAAP basis $900-$925 million $825-$850 million Net loss on a non-GAAP basis <$350 million <$275 million Cash, cash equivalents and short-term investments ~2.0 billion ~$2.0 billion
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
IONIS PHARMACEUTICALS INC entered into Collaboration and License Agreement with Metagenomi, Inc. valued at $80 million upfront fee, plus target selection fees, development/regulatory/sales milestones, and ro (effective 2022-11-10).
- Action
- entry
- Agreement
- license
- Counterparty
- Metagenomi, Inc.
- Value
- $80 million upfront fee, plus target selection fees, development/regulatory/sales milestones, and ro
- Effective
- 2022-11-10
Exact text from the filing
On November 10, 2022, Ionis Pharmaceuticals, Inc. (the “ Company ”) entered into a collaboration and license agreement (the “ Agreement ”) with Metagenomi, Inc. (“ Metagenomi ”) to research, develop and commercialize investigational medicines for up to eight potential genetic targets using gene editing technologies.
View on SEC.gov